ExploraMed V
Stage
Unattributed VC | AliveTotal Raised
$8.76MLast Raised
$8.76M | 5 yrs agoAbout ExploraMed V
ExploraMed is a medical technology incubation company dedicated to the identification, creation and development of medical device solutions. ExploraMed creates ideas in the fields of clinical, engineering, legal, strategic marketing, and financing, while focusing on efficient and timely development.
Missing: ExploraMed V's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: ExploraMed V's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing ExploraMed V
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ExploraMed V is included in 2 Expert Collections, including Medical Devices.
Medical Devices
8,603 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,901 items
ExploraMed V Patents
ExploraMed V has filed 49 patents.
The 3 most popular patent topics include:
- Breastfeeding
- Infant feeding
- Babycare
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/7/2018 | 12/27/2022 | Breastfeeding, Infancy, Infant feeding, Babycare, Midwifery | Grant |
Application Date | 8/7/2018 |
|---|---|
Grant Date | 12/27/2022 |
Title | |
Related Topics | Breastfeeding, Infancy, Infant feeding, Babycare, Midwifery |
Status | Grant |
Latest ExploraMed V News
Feb 19, 2013
Timothy Hay, (c) 2013 Dow Jones & Company, Inc. (c) 2013 Dow Jones & Company, Inc. Vibrynt Inc., a graduate from prestigious medical-technology incubator ExploraMed that had at one time been expected to be one of Australia's largest initial public offerings, has put itself up for sale after scrapping its IPO plans over the high cost of U.S. clinical trials for its obesity-treatment devices, VentureWire has learned. "We have a product that works, and we have the data to prove that, said Chief Executive Beverly Huss. "It's a tragedy for this space. There is an obesity epidemic in this country, and great technologies can't reach the market."... Document DJFVW00020130219e92jaub78
ExploraMed V Frequently Asked Questions (FAQ)
Where is ExploraMed V's headquarters?
ExploraMed V's headquarters is located at 2570 W. El Camino Real, Mountain View.
What is ExploraMed V's latest funding round?
ExploraMed V's latest funding round is Unattributed VC.
How much did ExploraMed V raise?
ExploraMed V raised a total of $8.76M.
Who are the investors of ExploraMed V?
Investors of ExploraMed V include New Enterprise Associates.
Who are ExploraMed V's competitors?
Competitors of ExploraMed V include Ivenix, Access Scientific, VytronUS, Vascular Pathways, GRAFTcath and 12 more.
Compare ExploraMed V to Competitors
a medical device company, based in part on intellectual property of CardioVascular Technologies, Inc. (http://cvtechinc.com), and is focused on the development and commercialization of the vascular access closure technology for the Interventional Cardiology market. The company is comprised of several seasoned medical device professionals and physicians, with a proven record of innovation, clinical acumen, access to the industry and successful commercialization of multiple medical device technologies.
GRAFTcath is a medical device company developing vascular access products for hemodialysis.
Hemosphere (formerly GRAFTcath) has developed a vascular access product that has the potential to reduce the risk of bacteremia, or severe infection, posed to catheter-dependent patients undergoing hemodialysis.
Claros Diagnostics is an early stage device company developing a POC multiplex diagnostic focused on a biomarker panel for prostate cancer.
Endothelix, Inc. is a cardiovascular device company focused on addressing inaccurate individualized prediction of cardiovascular risk and inadequate monitoring of the vascular response to treatments.
Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial (www.axialbiotech.com) is located in Salt Lake City, Utah.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.